arrow
T

Tomas Olsson

karolinska institutet
H指数:119
被引数:6.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Antibodies against MLC1 found in patients with NMOSD-like disease mediate astrocytopathy in rodent models

NMOSD样疾病患者中发现的抗MLC1抗体介导啮齿动物模型中的星形胶质细胞病变

2026-08-260
PRE
Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years

富马酸非那司提(ponesimod)在复发缓解型多发性硬化(RRMS)中的长期安全性和有效性:来自为期长达13年的随机Ⅱb期CORRE和扩展研究的成果

2026-08-010
PRE
A human pan-disease blood atlas of the circulating proteome

循环蛋白质组的人类泛疾病血液图谱

SCIENCE
IF45.8
2025-12-183
PRE
Co-exposure to PFAS and hydroxylated PCBs is associated with increased odds of multiple sclerosis

同时接触PFAS和羟基PCBs与多发性硬化症发病风险的增加相关。

2025-12-110
OAAI
Distinct transcriptomic and epigenomic responses of mature oligodendrocytes during disease progression in a mouse model of multiple sclerosis

在小鼠多发性硬化模型疾病进展过程中成熟少突胶质细胞的差异转录组与表观基因组反应

2025-11-170
OAAI
Epstein–Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA-DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis Onset

埃泼斯坦-巴尔病毒、维生素D水平低、日照不足以及HLA-DRB1*1501风险变异体通过共同的表观遗传通路导致多发性硬化症的发生。

2025-10-100
OAAI
Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis

抑郁症多基因性与多发性硬化疾病活动及残疾恶化

2025-08-070
OAAI
Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study (vol 271, pg 7250, 2024)

多发性硬化中Natalizumab临床反应的药物基因组学:一项全基因组多中心关联研究(卷271,页7250,2024)

2025-05-270
OA